The patent, entitled "Implant for the Treatment of Ligaments and Tendons," has been issued by the European Patent Office. Although similar injectable composition technology exists presently for use as dermal fillers, this new invention satisfies the need for orthopedics and spine procedures, such as treatment for Internal Disc Disruption (IDD), among other ligament and tendon repair procedures throughout the body, while providing ease-of-use benefits for the surgeon as well. The issued claims offer broad protection of a technology platform developed by Neville Alleyne, M.D. and Stuart Young, M.D.
"We are excited about our international patent portfolio especially as it pertains to licensing our products globally, as well as the increase in value of our intellectual property and therefore our Company," said SpineOvations CEO, M. Ross Simmonds. "This particular whole body patent protection provides us and our licensees with a strong marketing advantage over other products using similar active ingredients but it in limited applications. Additionally, SpineOvations looks forward to continuing to proactively build and strengthen its global intellectual property portfolio moving forward – including applications for the patented technology in the veterinary market."
Simmonds added that a key application of SpineOvations technology concept will also provide a method for alleviating pain symptoms in a potentially enormous population of patients by delivering appropriate amounts of collagen based material into ligaments and joints requiring repair.
SpineOvations is focused on the development of biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic applications, including non-surgical connective tissue repair. The companys technology platform consists of a novel, non-surgical application for identifying and treating spinal disc tears or fissures to seal and stabilize the structural integrity of the spinal disc.
SpineOvations new treatment concept integrates the use of discography with the administration of the companys DiscSeal™, an injectable agent for soft tissue engineering, designed to fill and seal the disc defect and provide internal disc stabilization and pain relief for the millions of patients with chronic back pain as a result of internal disc derangement (IDD). This innovative approach offers the potential to provide a cost-effective treatment option for patients with chronic back pain that will delay or possibly prevent the need for more invasive treatments such as surgery for spinal fusion or disc replacement.
SpineOvations is a San Diego-based, privately held medical device company focused on the development of novel, biocompatible injectables for the stabilization of spinal disc integrity and for other orthopedic and whole-body applications including non-surgical connective tissue repair. The companys technology platform consists of a novel non-surgical application for identifying and treating spinal discs that have tears or fissures in order to seal the defect and improve structural integrity.
SpineOvations DiscSeal™ is a percutaneous injection treatment for patients with Internal Disc Derangement (IDD) and suffering from chronic, discogenic lower back pain. DiscSeal is designed to be an early-stage treatment for those patients who have failed conservative care and who are not yet candidates for the invasive surgical treatment options of total disc replacement or spinal fusion, the largest segment of the spine market. For more information, visit: http://www.spineovations.com/